To estimate approximate doses of rosuvastatin equivalent to the other hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) for a temporary substitution program.
DATA SOURCES:
A literature search was conducted to locate clinical trials directly comparing rosuvastatin with other statins that evaluated the magnitude of cholesterol lowering.
DATA SYNTHESIS:
The mean low-density lipoprotein and total cholesterol values from the clinical trials were assessed. Study results indicate that rosuvastatin is not equivalent to other statins on a milligram-to-milligram basis.
CONCLUSIONS:
Rosuvastatin appears to be at least 2 and 4 times as potent as atorvastatin and simvastatin, respectively, and at least 8 times as potent as pravastatin and lovastatin.
Guidelines for therapeutic interchange. American College of Clinical Pharmacy. Pharmacotherapy1993;13:252–6.
2.
StoysichAMassoomiF.Automatic interchange of the ACE inhibitors: Decision-making process and initial results. Formulary2002;37:41–4.
3.
LevyRASmithDL.Clinical differences among nonsteroidal antiinflammatory drugs: Implications for therapeutic substitution in ambulatory patients. DICP1989;23:76–85.
4.
SaffelDMarascoRASengsonS.Outcomes based therapeutic interchange: An ACE inhibitor interchange program. Consult Pharm1999;14:65–71.
5.
HillemanDEMohiuddianSMWurdemanRLWadibiaEC.Outcomes and cost savings of an ACE inhibitor therapeutic interchange. J Managed Care Pharm1997;3:219–23.
6.
SmithGMHarperIMStowersAD.A cost analysis of switching calcium channel blockers: A one-year post-formulary decision review. P&T2002;27:333–7,344.
7.
SchachtnerJMGuharoyRMedicisJJNewmanNSpeizerR.Prevalence and cost savings of therapeutic interchange among U.S. hospitals. Am J Health Syst Pharm2002;59:529–33.
8.
GraceKASwieckiJHyattRGibbsHJonesDLSheikhM.Implementation of a therapeutic-interchange clinic for HMG-CoA reductase inhibitors. Am J Health Syst Pharm2002;59:1077–82.
9.
HillemanDWurdemanRLLenzTL.Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease. Pharmacotherapy2001;21:410–5.
10.
JonesPHDavidsonMHSteinEABaysHEMcKenneyJMMillerEComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol2003;92:152–60.
11.
DavidsonMMaPSteinEAGottoAMJrRazaAChitraRComparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol2002;89:268–75.
12.
SchneckDWKnoppRHBallantyneCMMcPhersonRChitraRRSimonsonSG.Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol2003;91:33–41.
13.
OlssonAGIstadHLuurilaOOseLStenderSTuomilehtoJEffects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J2002;144:1044–51.
14.
BrownWVBaysHEHassmanDRMcKenneyJChitraRHutchinsonHEfficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J2002;144:1036–43.
15.
PaolettiRFahmyMGerhardMMizanJSouthworthH.Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study. J Cardiovasc Risk2001;8:383–90.
16.
OlssonAGPearsJMcKellarJMizanJRazaA.Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol2001;88:504–8.
17.
BrewerHB.Benefit—risk assessment of rosuvastatin 10 to 40 mg. Am J Cardiol2003;92:23K–9K.
18.
SteinEAStruttKSouthworthHDigglePJMillerEfor the HeFH Study Group. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol2003;92:1287–93.
19.
JonesPKafonekSLauroraIHunninghakeD.Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol1998;81:582–7.
20.
BrownASBakker-ArkemaRGYellenLHenleyRWJrGuthrieRCampbellCFTreating patients with documented atherosclerosis to National Cholesterol Education Program—recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol1998;32:665–72.
21.
HunninghakeDBakker-ArkemaRGWigandJPDrehoblMSchrottHEarlyJLTreating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract1998;47:349–56.
22.
IllingsworthDRSteinEAKnoppRHHunninghakeDBDavissonMHDujovneCAA randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. J Cardiovasc Pharmacol Ther1996;1:23–30.
PasternakRCSmithSCBairey-MerzCNGrundySMCleemanJILenfantC.ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke2002;33:2337–41.
26.
WolffenbuttelBHMahlaGMullerDPentrupABlackDM.Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia. Neth J Med1998;52:131–7.
